Andrew M Yeager

Interests

Research

Clinical and translational research in hematopoietic cell transplantation (HCT) and acute leukemias

Teaching

Education of medical students, internal medicine residents, and hematology/medical oncology fellows

Courses

No activities entered.

Scholarly Contributions

Journals/Publications

• Shenoy, S., Shetty, S., Lankala, S., Anwer, F., Yeager, A., & Adigopula, S. (2017). Cardiovascular Oncologic Emergencies. Cardiology, 138(3), 147-158.
  More info

  Oncologic emergencies can present either as a progression of a known cancer or as the initial presentation of a previously undiagnosed cancer. In most of these situations, a very high degree of suspicion is required to allow prompt assessment, diagnosis, and treatment. In this article, we review the presentation and management of cardiovascular oncologic emergencies from primary and metastatic tumors of the heart and complications such as pericardial tamponade, superior vena cava syndrome, and hyperviscosity syndrome. We have included the cardiovascular complications from radiation therapy, chemotherapeutic agents, and biologic agents used in modern cancer treatment.
• Diri, R., Anwer, F., Yeager, A., Krishnadasan, R., & McBride, A. (2016). Retrospective review of intravenous pentamidine for Pneumocystis pneumonia prophylaxis in allogeneic hematopoietic stem cell transplantation. Transplant infectious disease : an official journal of the Transplantation Society, 18(1), 63-9.
  More info

  Patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) are at risk of numerous opportunistic infections. Pneumocystis jirovecii pneumonia (PJP) is a potentially life-threatening infection that can develop in immunocompromised individuals. Current prophylaxis for PJP includes trimethoprim-sulfamethoxazole (TMP-SMX), dapsone, atovaquone, or inhaled pentamidine (PEN), often with varying breakthrough rates. The use of intravenous (IV) PEN for PJP prophylaxis has been evaluated in pediatric patients.
• Menon, N. N., Jenkins, L. M., Cui, H., Jenkins, C., Anwer, F., Yeager, A. M., & Katsanis, E. (2016). Factors associated with improved outcomes after second allogeneic hematopoietic cell transplantation for relapsed pediatric leukemia. Annals of hematology, 95(4), 637-44.
  More info

  A second allogeneic (allo) hematopoietic cell transplant (HCT) is an important therapeutic consideration for patients relapsing after their first. We conducted a retrospective review of 41 pediatric patients with leukemia that underwent a second allo-HCT at our institution. Overall, 53.7 and 43.9 % of patients were alive and disease-free at 1 and 5 years, respectively, after the second allo-HCT. The factors affecting outcome by both univariate and multivariate analysis were interval between transplants and the use of a myeloablative conditioning (MAC) regimen prior to second transplant. Outcomes were inferior in patients who received their second transplant
• Taverna, J. A., Yun, S. G., Jonnadula, J., Saleh, A., Riaz, I. B., Abraham, I., Yeager, A. M., Persky, D. O., McBride, A., Haldar, S., & Anwer, F. (2016). Role of Maintenance Therapy after High-Dose Chemotherapy and Autologous Hematopoietic Cell Transplantation in Aggressive Lymphomas: A Systematic Review. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
  More info

  Significant uncertainty exists in regard to the efficacy of maintenance therapy after high-dose chemotherapy (HDC) as well as autologous stem cell transplantation (ASCT) for the treatment of patients with aggressive lymphoma. A systematic review was performed to evaluate the effectiveness of post-ASCT maintenance therapy in patients with relapsed/refractory lymphoma. A comprehensive literature search yielded 4476 studies and a total of 42 studies (11 randomized controlled trials [RCT], 9 retrospective comparative studies, and 22 single-arm studies) were included in the systematic review. There was significant heterogeneity in study design, chemotherapeutic regimens, post-ASCT maintenance strategies, patient enrollment criteria, and study endpoints. Our findings suggest that post-ASCT maintenance immune-targeting strategies, including PD-1/PD-L1 blocking antibodies, rituximab, and brentuximab, may improve progression-free survival but not overall survival. Collectively, the results indicate a need for testing new strategies with well-designed and adequately powered RCTs to better address the role of post-ASCT maintenance in relapsed/refractory lymphomas.
• Yeager, A. M. (2016). Cellular Transplant for Globoid Cell Leukodystrophy: Preclinical and Clinical Observations. Journal of Neuroscience Research, 22, 1182-1196.
• Yeager, A. M. (2016). Cost and Outcome Analysis of Autologous Peripheral Blood Stem Cell Mobilization with Plerixafor and G-CSF vs. Cyclosphosphamide and G-CSF in Patients with Multiple Myeloma: A Reassessment in View of Increased Costs of Cyclophosphamide. Biology of Blood and Marrow Transplantation.
  More info

  Volume 22: S270 (abstract no. 390)
• Houghtelin, A. B., Kopp, L. M., Pelayo-Katsanis, L., Kuo, P. H., Yeager, A. M., & Katsanis, E. (2015). Extramedullary Breast Relapse of Acute Lymphoblastic Leukemia Controlled with a Second Allogeneic/Autologous Hematopoietic Cell Transplant. Journal of adolescent and young adult oncology, 4(1), 50-3.
  More info

  Relapse of acute lymphoblastic leukemia (ALL) in the breast is uncommon and often precedes systemic relapse, resulting in poor survival. We report the development of breast involvement of ALL in a 20-year-old woman 32 months after a related allogeneic peripheral blood hematopoietic cell transplantation (PBHCT) in first remission. This extramedullary relapse occurred in the continuous presence of complete donor chimerism. After systemic re-induction chemotherapy and a second PBHCT using donor cells that had been cryopreserved at first transplant, our patient has remained in second complete remission for more than 44 months.
• Nadeau, M., George, L., Yeager, A. M., Anwer, F., & McBride, A. (2015). Plerixafor as a salvage mobilization strategy for haploidentical peripheral blood allogeneic stem cell transplantation. Clinical case reports, 3(9), 728-30.
  More info

  In allogeneic stem cell mobilization, peripheral blood stem cell mobilization with filgrastim can be considered standard of care. Poor mobilizers may be at risk for inadequate stem cell collection during apheresis. He we present a successful case of salvage plerixafor use with filgrastim in a haploidentical identical transplant patient.
• Sundararajan, S., Chen, H., Kumar, A., Tus, K., Yeager, A., & Puvvada, S. (2015). Donor-derived marginal zone lymphoma following reduced-intensity allogeneic peripheral blood stem cell transplant. Leukemia & lymphoma, 1-4.
• Yeager, A. M. (2015). Efficacy of Pharmacokinetic-Directed Busulfan, Cyclophosphamide and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase 2 Study and CIBMTR Outcomes. Biology of Blood and Marrow Transplantation.
• Yeager, A. M. (2015). Retrospective Review of Intravenous Pentamidine for Pneumocystis Pneumonia Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Infectious Disease, 18, 63-69.
• Green, M. R., Acharya, U. H., & Yeager, A. M. (2013). Is fidaxomicin the drug of choice for treating Clostridium difficile-associated diarrhea in patients with cancer?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 31(34), 4376-8.
• Kantarjian, H. M., Erba, H. P., Claxton, D., Arellano, M., Lyons, R. M., Kovascovics, T., Gabrilove, J., Craig, M., Douer, D., Maris, M., Petersdorf, S., Shami, P. J., Yeager, A. M., Eckert, S., Abichandani, R., & Faderl, S. (2010). Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28(4), 549-55.
  More info

  This phase II study assessed clofarabine monotherapy in older adults (>or= 60 years of age) with untreated acute myeloid leukemia (AML) and at least one unfavorable baseline prognostic factor.
• Wall, D. A., Chan, K. W., Nieder, M. L., Hayashi, R. J., Yeager, A. M., Kadota, R., Przepiorka, D., Mezzi, K., Kletzel, M., & , P. B. (2010). Safety, efficacy, and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation. Pediatric blood & cancer, 54(2), 291-8.
  More info

  To determine the safety, efficacy, and PK profile of intravenous busulfan (Bu) in the context of a Bu and cyclophosphamide (IVBuCy) preparative regimen in children undergoing allogeneic hematopoietic stem cell transplantation (HSCT).
• Stiff, P. J., Bensinger, W., Abidi, M. H., Gingrich, R., Artz, A. S., Nademanee, A., Hansen, K. S., Sobczak, C., Cutler, C., Bolwell, B., Shore, T. B., Lazarus, H. M., Yeager, A. M., Lovelace, W., Guo, M., & Dreiling, L. (2009). Clinical and ultrasonic evaluation of spleen size during peripheral blood progenitor cell mobilization by filgrastim: results of an open-label trial in normal donors. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 15(7), 827-34.
  More info

  Rare reports of splenic rupture have been associated with filgrastim treatment during peripheral blood progenitor cell (PBPC) mobilization in allogeneic donors. We performed a prospective study of spleen volume change in 309 normal donors who received filgrastim according to local institutional practices. Splenic assessments consisted of ultrasonography and clinical examination at baseline and on the first day of leukapheresis in 304 donors. Of these, 90 donors were also examined 2 and 4 days after the first leukapheresis and 7 days after the last leukapheresis. Median spleen volume increased 1.47-fold (range: 0.63 to 2.60) on the first leukapheresis day and declined to near pretreatment levels at 7 days after last leukapheresis. Nine percent of donors had > or =2-fold increase in splenic volume. Spleen palpability did not correlate with change in spleen volume. No donors experienced a splenic rupture. There was no correlation between change in spleen volume and filgrastim dosage, number of doses/day, peak absolute neutrophil count (ANC), CD34+ yield, or donor baseline weight. Most donors experienced > or =1 adverse event, with 6 donors reporting serious adverse events. We conclude that the increase in splenic volume during PBPC mobilization in donors was transient, and that filgrastim was well tolerated in this study. This trial was registered at www.ClinicalTrials.gov as NCT00115128.

Poster Presentations

• Yeager, A. M. (2017, February). Allogeneic Hematopoietic Cell Transplantation (HCT) in the Eighth Decade of Life: How Much Does Age Matter?. Annual Tandem BMT Meeeting. Orlando, FL: American Society for Blood and Marrow Transplantation.
  More info

  Sorror, M.L., Sandmaier, B.M., Storer, B., Chauncey, T., Shizuru, J., Franke, G.N., Pulsipher, M., Maris, M., Bruno, B., Andersen, N.S., Hari, P., Langston, A., Agura, E., Sahebi, F., Maziarz, R., Petersen, F., Bethge, W., Gutman, J., Olesen, G., Yeager, A., Hubel, K., Hogan, W., Mielcarek, M., Georges, G., Maloney, D.G., and Storb, R. Allogeneic Hematopoietic Cell Transplantation (HCT) in the Eighth Decade of Life: How Much Does Age Matter? Biol. Blood Marrow Transplant. 23: S85, 2017 (abstract no. 87).
• Yeager, A. M. (2017, February). Fluconazole 200 mg Daily As Antifungal Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients: A Retrospective Review. Annual Tandem BMT Meeeting. Orlando, FL: American Society for Blood and Marrow Transplantation.
  More info

  Maher, K.R., McBride, A., Chen, C.C.M., Lim, M., Majeed, A., Hunt, T., Farooqui, S.R., Riddle, Z., Yeager, A.M., and Anwer, F. Fluconazole 200 mg Daily As Antifungal Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients: A Retrospective Review. Biol. Blood Marrow Transplant. 23: S181, 2017 (abstract no. 230).
• Yeager, A. M. (2017, February). PD or Not PD? Optimal Management of Dialysis-Dependent Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation. Annual Tandem BMT Meeting. Orlando, FL: American Society for Blood and Marrow Transplantation.
  More info

  Park, S., Saleem, K., Sussman, A., and Yeager, A.M. PD or Not PD? Optimal Management of Dialysis-Dependent Patients Undergoing Autologous Peripheral Blood Stem Cell Transplantation. Biol. Blood Marrow Transplant. 23: S225, 2017 (abstract no. 298).
• Yeager, A. M. (2017, November). Health State Utilities Associated with Treatment Options for Acute Myeloid Leukemia (AML). International Society for Pharmacoeconomics and Outcomes Research 20th Annual European Congress. Glasgow, Scotland, U.K: International Society for Pharmacoeconomics and Outcomes Research.
  More info

  Matza, L.S., Deger, K., Howell, T., Hillgruber, N.K., Koetter, K., Yeager, A.M., Hogge, D., Fisher, V., Louie, A.C., and Chung, K.C. Health State Utilities Associated with Treatment Options for Acute Myeloid Leukemia (AML). International Society for Pharmacoeconomics and Outcomes Research 20th Annual European Congress, Glasgow, Scotland, U.K., 4-8 November 2017.
• Yeager, A. M. (2017, October). Disseminated Coccidioidomycosis Masquerading as Recurrent Lymphoma. American College of Physicians-Arizona Chapter Annual Meeting. Tucson, AZ: American College of Physicians - Arizona Chapter.
  More info

  Manning, M., Kuo, P., and Yeager, A.M. Disseminated Coccidioidomycosis Masquerading as Recurrent Lymphoma. Poster presentation, American College of Physicians-Arizona Chapter, Tucson, AZ, 20-22 October 2017.
• Yeager, A. M. (2015, February 2015). Retrospective Review of Intravenous Pentamadine for Pneumonia Prophylaxis in Patients Undergoing Hematopoietic Stem Cell Transplantation. Tandem ASBMT Meeting.

Case Studies

• Yeager, A. M. (2016. Polycythemia Associated with Multiple Myeloma(pp 216686 published online).